Olezarsen not checked

Ionis Pharmaceuticals, Inc. · ISIS 678354

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
4 active
11 in total · 6 in the EU
Targets
 

What this is

How it works
A short strand of genetic material that blocks one gene's message, so the body makes less of one protein.APOC-III-directed RNA Interaction; Antisense Oligonucleotide FDA class
Tested for
Familial Chylomicronemia Syndrome (3 trials), Severe Hypertriglyceridemia
Main trialPhase 3
“The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.”In the company’s words, NCT05681351 on ClinicalTrials.gov
Other names
ISIS 678354 · AKCEA-APOCIII-LRx · IONIS-APOCIII-LRx

Other drugs for Familial Chylomicronemia Syndrome

All 2 drugs for Familial Chylomicronemia Syndrome

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Mar 2027 CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Phase 3Active, not recruiting Jun 2027 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Phase 3Active, not recruiting Feb 2028 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Phase 3Recruiting Aug 2030 A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Phase 3Completed 14 Jul 2023 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
Phase 3Completed 8 Aug 2024 A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
Phase 3Completed 22 Oct 2024 A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Phase 3Completed 17 Dec 2024 A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
Phase 2Completed 25 Nov 2019 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
Phase 2Completed 22 Mar 2023 A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Phase 1Completed 22 May 2023 A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Olezarsen

Following is part of Solo: you see every change to Olezarsen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in